Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer
NCT02591667Phase 2Unknown
- Sponsor
- Medical University of Vienna
- Start
- Mar 2016
- Primary completion
- Feb 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil in colorectal cancer (CRC), peritoneal metastasis (PM), sponsored by Medical University of Vienna. Status: unknown.
02
Drugs
bevacizumaboxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
colorectal cancer (CRC)peritoneal metastasis (PM)
Beyond the preview
Go deeper on NCT02591667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591667.